Editing the Genome Without Double-Stranded DNA Breaks.
Alexis C Komor, Ahmed H Badran, David R Liu
https://pubmed.ncbi.nlm.nih.gov/28957631/Actively Recruiting
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-11-03
15
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating a gene therapy approach using base-edited autologous hematopoietic stem and progenitor cells HSPCs to treat males aged 18 to 75 with X-linked Chronic Granulomatous Disease X-CGD, a rare immune disorder caused by mutations in the CYBB gene. The study aims to evaluate the safety and effectiveness of this single infusion treatment in improving white blood cell function and reducing infections related to CGD. Participants will first undergo stem cell collection through apheresis during the development phase. In the treatment phase, they will receive Campath alemtuzumab to reduce immune response risk, followed by chemotherapy with busulfan to condition the body for the infusion of the base-edited stem cells. They will also take sirolimus for 3 to 6 months to further prevent immune reactions. Additional medications like Palifermin, Filgrastim, and Plerixafor are used to support the treatment process. Throughout the study, participants will have follow-up visits at months 3, 6, 12, 18, 24, and yearly up to 5 years, with continued monitoring up to 15 years under a separate protocol. Assessments include safety checks, blood tests for gene repair and immune function, DNA sequencing for gene editing accuracy, and tracking clinical benefits such as infection rates. The study measures both short-term and long-term effects of the gene therapy.
CONDITIONS
Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease
S
Suk S De Ravin, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational Base‑edited HSPC (single‑group trial) | Allogeneic hematopoietic stem cell transplant (current curative care) |
|---|---|---|
| What it is | Investigational autologous base‑edited CD34+ hematopoietic stem and progenitor cell infusion given as a single therapy after conditioning | Established allogeneic hematopoietic stem cell transplant (HSCT) using donor cells |
| Role in trial | Investigational treatment administered to all enrolled participants | Not part of the study; serves as outside context |
| Primary use | To repair CYBB mutation using base editing and reconstitute functional phagocytes | Curative replacement of defective hematopoietic system |
| How it is given or performed | Single intravenous infusion of autologous base‑edited HSPC after conditioning | Infusion of donor hematopoietic cells following conditioning regimen |
| Evidence status | Early‑phase investigational therapy; safety and efficacy under evaluation | Proven curative option with substantial survival benefit in CGD |
| Important risks | Under investigation; risks not yet fully defined | Includes risks of graft‑versus‑host disease, transplant‑related toxicity |
| Important limitations | Small early‑phase single‑arm study without direct comparator; long‑term durability unknown | Requires donor availability and involves significant risks and morbidity |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility including genetic mutation confirmation and clinical stability assessment.
1 to 2 visits
Duration - Up to 1 week
Participants undergo apheresis to collect hematopoietic stem and progenitor cells for base editing development and validation.
1 visit for stem cell collection
Duration - Approximately 3 to 6 months for immunomodulation and infusion procedures
Participants receive immunomodulating agents Campath and sirolimus, conditioning chemotherapy with busulfan, and a one-time infusion of base-edited stem cells.
Multiple visits including daily dosing and infusion procedures
Duration - 5 years active follow-up, with monitoring continuing up to 15 years under separate protocol
Participants have scheduled evaluations to monitor safety, gene editing effectiveness, immune function, and clinical status over several years.
Visits at months 3, 6, 12, 18, 24, then yearly
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Alexis C Komor, Ahmed H Badran, David R Liu
https://pubmed.ncbi.nlm.nih.gov/28957631/Vera Bzhilyanskaya, Linyuan Ma, Siyuan Liu...
https://pubmed.ncbi.nlm.nih.gov/39413163/Douglas B Kuhns, W Gregory Alvord, Theo Heller...
https://pubmed.ncbi.nlm.nih.gov/21190454/National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor